Mark Massaro

“Maybe the first one, obviously, it looks like the true-up number dropped by approximately 6 million or so in Q2 relative to Q1.”

“So, I wanted to start in the life science diagnostic tool space. You know, Stephen, you called out a bunch of areas, notably liquid biopsy. I guess, if you could, could you kind of double-click in there?”

“I wanted to ask about the myositis launch. Can you just give us a sense for what we should be on the lookout for in terms of any data readouts, timing, and then can you give us maybe a sneak preview on how you're thinking about pricing the test?”

“I was hoping that maybe you could double-click on the Carillon opportunity, recognizing that that is a very, very significant lift that you talked about. But I was just wondering if you could maybe frame what needs to happen next.”

“I wanted to start maybe just to clarify the higher pricing assumptions on XT, CDX, or pardon me, the XF. Maybe can you just walk us through what rates or what prices are you estimating on the Medicare side?”